Novavax, Inc.

Novavax, Inc. is a Gaithersburg, Maryland-based vaccine biotechnology company founded in 1987 and listed on NASDAQ (ticker: NVAX), best known for developing protein subunit vaccines using its proprietary Matrix-M adjuvant platform. Unlike mRNA or viral-vector approaches, Novavax produces recombinant nanoparticle antigens that mimic the surface of a pathogen, pairing them with Matrix-M, a saponin-based formulation derived from the Quillaja saponaria tree, to generate robust immune responses with a well-characterised tolerability profile.

NVX-CoV2373 and COVID-19 Programme

Novavax received its first major regulatory milestones through its COVID-19 vaccine, NVX-CoV2373, marketed as Nuvaxovid. The vaccine secured Emergency Use Authorisation from the US FDA, conditional marketing authorisation from the European Medicines Agency, and approvals in numerous countries across Asia-Pacific, Europe, and the Americas. Nuvaxovid became a significant addition to global vaccination campaigns as a protein-based alternative for individuals who preferred a non-mRNA option, with the World Health Organization granting it Emergency Use Listing. Updated formulations targeting later SARS-CoV-2 variants have continued to advance through regulatory review.

Pipeline and Strategic Partnerships

Beyond COVID-19, Novavax applies its platform to influenza vaccines, with a quadrivalent recombinant candidate in late-stage development, and combination respiratory programmes including a COVID-influenza co-formulation. The company has historically held collaboration agreements with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Bill & Melinda Gates Foundation, and has executed manufacturing and supply partnerships with organisations including Serum Institute of India to support large-scale global distribution.

Novavax's corporate growth strategy centres on out-licensing the Matrix-M adjuvant to third-party vaccine developers, extending the platform's reach across a broad range of infectious-disease targets. The company publishes peer-reviewed scientific findings through a dedicated publications resource and maintains transparency with the research and investment communities through its public filings and investor relations programme.

Further information is available at novavax.com.